1. Groschwitz KR, Hogan SP: Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009;124: 3-20.
2. Kagnoff MF: The intestinal epithelium is an integral component of a communications network. J Clin Invest 2014;127: 2841-2843.
3. Pelaseyed T, Bergström JH, Ermud A, et al: The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev 2014;260: 8-20.
4. Derrien M, van Passel MW, van de Bovenkamp JH, et al: Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes 2010;1: 254-268.
5. Kato K, Lillehoj EP, Kim KC: Pseudomonas aeruginosa stimulates tyrosine phosphorylation of and TLR5 association with the MUC1 cytoplasmic tail through EGFR activation. Inflamm Res 2016;65: 225-233.
6. Chelakkat C, Ghim J, Ryu SH: Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med 2018;50: 103.
7. Lauloetter MG, Nava P, Lee WY, et a: JAM-A regulates permeability and inflammation in the intestine in vivo. J Exp Med 2007;204: 3067-3076.
8. Colegio OR, Van Itallie CM, McCrea HJ, et al: Claudins create charge-selective channels in the paracellular pathway between epithelial cells. Am J Physiol Cell Physiol 2002;283: 142-147.
9. 伊藤雅彦: 上皮構造とバリア機能の調節分子機構. 生化学 2013;85: 582-585.
10. Umeda K, Ikenouchi J, Katarira-Tayama S, et al: ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 2006;126: 741-754.
11. Yamazaki Y, Umeda K, Wada M, et al: ZO-1- and ZO-2-dependent integration of myosin-2 to epithelial zonula adherens. Mol Biol Cell 2008; 19: 3801-3811.
12. Ceponis PJ, Botelho F, Richards CD, et al: Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. J Biol Chem 2000;275: 29132-29137.
13. Clayburgh DR, Musch MW, Leitges M, et al: Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest 2006;116: 2682-2694.
14. Madsen KL, Malfair D, Gray D, et al: Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999;5: 262-270.
15. Berkes J, Viswanathan VK, Savkovic SD, et al: Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003;52: 439-451.
16. Muza-Moons MM, Schneeberger EE, Hecht GA: Enteropathogenic Escherichia coli infection leads to appearance of aberrant tight junctions strands in the lateral membrane of intestinal epithelial cells. Cell Microbiol 2004;6: 783-793.
17. Meddings J: The significance of the gut barrier in disease. Gut 2008;57: 438- 440.
18. Bjarnason I, Peters TJ: In vitro determination of small intestinal permeability: demonstration of a persistent defect in patients with coeliac disease. Gut 1984;25: 145-150.
19. Yamamoto S, Ma X: Role of Nod2 in the development of Crohn's disease. Microbs Infect 2009;11: 912-918.
20. Shimizu H, Ohue-Kitano R, Kimura I: Regulation of host energy metabolism by gut microbiota-derived short-chain fatty acids. Glycative Stress Research 2019;6: 181-191.
21. Tan J, Mckenzie C, Vuillermin, et al: Dietary Fiber and Bacterial SCFA Enhance Oral Tolerance and Protect against Food Allergy through Diverse Cellular Pathways. Cell Rep 2016;15: 2809-2824.
22. Paparo L, Costanzo M, di Scala C, et al: The influence of early life nutrition on epigenetic regulatory mechanisms of the immune system. Nutrients 2014;6: 4706-4719.
23. Zheng J, Yuan X, Zhang C, et al: N-Acetylcysteine alleviates gut dysbiosis and glucose metabolic disorder in high-fat diet-fed mice. J Diabetes 2019;11: 32-45.
24. Samuel BS, Shaito A, Motoike T, et al: Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein- coupled receptor, Gpr41. Proc Natl Acad Sci USA 2008;105: 16767–16772.
25. Arora T, Bäckhed F: The gut microbiota and metabolic disease: current understanding and future perspectives. J Intern Med 2016:280: 339-349.
26. Chang I, Kim JD: Inhibition of Aflatoxin Production of Aspergillus flavus by Lactobacillus casei. Mycobiology 2007;35: 76-81.
27. Wang X, Zhang M, Wang W, et al: The in vitro Effects of the Probiotic Strain, Lactobacillus casei ZX633 on Gut Microbiota Composition in Infants With Diarrhea. Front Cell Infect Microbiol 2020; 10.
28. Brennan CA, Garrett WS: Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol 2019;17: 156-166.
29. Hu L, Lu W, Wang L, et al: Assessment of Bifidobacterium Species Using groEL Gene on the Basis of Illumina MiSeq High-Throughput Sequencing. Genes (Basel) 2017;8.
30. Arboleya S, Watkins C, Stanton C, et al: Gut Bifidobacteria Populations in Human Health and Aging. Front Microbiol 2016;7.
31. Wexler HM: Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007;20: 593-621.
32. Dworkin M, Falkow S, Rosenberg E, et al: The Prokaryotes. Second Edition 2006.
33. Brook I: Anaerobic Bacteria. Infectious Diseases (Fourth Edition) Volume2 2017; 1628-1644.
34. Bouter KE, van Raalte DH, Groen AK, et al: Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. Gastroenterology 2017;152: 1671-1678.
35. Singh N, Gurav A, Sivaprakasam S, et al: Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014;40: 128-139.
36. Macia L, Tan J, Vieira AT, et al: Metabolite-sensing receptor GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun 2015;6.
37. Roda A, Simoni P, Magliulo M, et al: A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol 2007;13: 1079-1084.
38. Vernia P, Monteleone G, Grandinetti G, et al: Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci 2000;45: 976-981.
39. Suzuki T: Regulation of the intestinal barrier by nutrients: The role of tight junctions. Anim Sci J 2020;91.
40. Srinivasan B, Kolli AR, Esch MB, et al: TEER measurement techniques for in vitro barrier model systems. J Lab Autom 2015;20: 107-126.
41. D'Agostino EM, Rossetti D, Atkins D, et al: Interaction of tea polyphenols and food constituents with model gut epithelia: the protective role of the mucus gel layer. J Agric Food Chem 2012;60; 3318-3328.
42. Keely S, Rullay A, Wilson C, et al: In vitro and ex vivo intestinal tissue models to measure mucoadhesion of poly (methacrylate) and N-trimethylated chitosan polymers. Pharm Res 2005;22: 38-49.
43. Pullan RD, Thomas GA, Rhodes M, et al: Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994;35: 353-359.
44. Leteurtre E, Gouyer V, Rousseau K, et al: Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell 2004;96: 145-151.
45. Tralongo P, Tomasello G, Damiani P, et al: The role of butyric acid as a protective agent against inflammatory bowel diseases. EMBJ 2014;9: 24-35.
46. Zommiti M, Cambronel M, Maillot O, et al: Evaluation of Probiotic Properties and Safety of Enterococcus faecium Isolated From Artisanal Tunisian Meat "Dried Ossban". Front Microbiol 2018;9.
47. Deng H, Yang S, Zhang Y, et al: Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation. Front Microbiol 2018;9: 2976.
48. Yang X, Gao XC, Liu J, et al: Effect of EPEC endotoxin and bifidobacteria on intestinal barrier function through modulation of toll-like receptor 2 and toll- like receptor 4 expression in intestinal epithelial cell-18. World J Gastroenteral 2017;23: 4744-4751.
49. Abdulkareem AA, Shelton RM, Landini G, et al: Periodontal pathogens promote epithelial-mesenchymal transition in oral squamous carcinoma cells in vitro. Cell Adh Migr 2018;12: 127-123.
50. Furuse M, Hata M, Furuse K, et al: Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002;156: 1099-1111.
51. Itoh M, Furuse M, Morita K, et al: Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J Cell Biol 1999;147: 1351-1363.
52. Johansson ME, Phillipson M, Petersson J, et al: The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acid Sci U S A 2008;105: 15064-15069.
53. Allen A, Flemström G: Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol 2005;188: C1-C19.
54. Adrian A: Mucus- a protective secretion of complexity. Trends Biochem Sci 1983; 8: 169-173.
55. Deplancke B, Gaskins HR: Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr 2001;73: 1131-1141.
56. Collins LM, Dawes C: The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J Dent Rea 1987;66: 1300-1302.
57. Atuma C, Strugala V, Allen A, et al: The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001;280: 922-929.
58. Desseyn JL, Aubert JP, Porchet N, et al: Evolution of the large secreted gel- forming mucins. Mol Biol Evol 2000;17: 1178-1184.
59. Dekker J, Rossen JW, Büller HA, et al: The MUC family: an obituary. Trends Biochem Sci 2002;27: 126-131.
60. Roberton AM, Mckenzie CG, Sharfe N, et al: A glycosulphatase that removes sulphate from mucus glycoprotein. Biochem J 1993;293: 683-689.
61. Brockhausen I: Sulphotransferases acting on mucin-type oligosaccharides. Biochem Soc Trans 2003;31: 318-325.
62. Corfield AP, Shukla AK: Mucins: Vital components of the mucosal defensive barrier. Am Gen Prot Technol 2003;3: 20-23.
63. Tokés AM, Kulka J, Paku S, et al: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Epub 2005;7: 296-305.
64. Neunlist M, Toumi F, Oreschkova T, et al: Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am J Physiol Gastrointest Liver Physiol 2003;285: 1028- 1036.
65. Pedersen G: Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. Dan Med J 2015;62.
66. Cobo ER, Kissoon-Singh V, Moreau F, et al: Colonic MUC2 mucin regulates the expression and antimicrobial activity of β-defensin 2. Mucosal Immunol 2015;8: 1360-1372.
67. Sperandio B, Fischer N, Joncquel Chevalier-Curt M, et al: Virulent Shigella flexneri Affects Secretion, Expression, and Glycosylation of Gel-Forming Mucins in Mucus-Producing Cells. Infect Immun 2013;81: 3632-3643.
68. Cairns MT, Gupta A, Naughton JA, et al: Glycosylation-related gene expression in HT29-MTX-E12 cells upon infection by Helicobacter pylori. World J Gastroenterol 2017;23: 6817-6832.
69. Jacobsen AV, Yemaneab BT, Jass J, et al: Reference gene selection for qPCR is dependent on cell type rather than treatment in colonic and vaginal human epithelial cell lines. PLos One 2017;9.
70. Yu AS, Enck AH, Lencer WI, et al: Claudin-8 expression in Madin-Darby canine kidney cells augments the paracellular barrier to cation permeation. J Biol Chem 2003;278: 17350-17359.
71. Furuse M, Sasaki H, Tsukita S: Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 1999;147: 891-903.
72. 芦田久: 消化管ムチンを介した微生物と宿主の相互作用. 化学と生物 2016;54: 901-908.
73. Carraway KL, Fregien N: Mucin structure and function: insights from molecular biology. Trends in Glycoscience and Glycotechnology 1995;7: 31-44.
74. Martín-Sosa S, Martín MJ, Hueso P: The sialylated fraction of milk oligosaccharides is partially responsible for binding to enterotoxigenic and uropathogenic Escherichia coli human strains. J Nutr 2002;132: 3067-3072.
75. Yolken RH, Peterson JA, Vonderfecht, et al: Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. J Clin Inveat 1992;90: 1984-1991.
76. Ruiz-Palacios GM, Cervantes LE, Romas P, et al: Campylobacter jejuni binds intestinal H(O) antigen (Fucα1, 2Galβ1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 2003;278: 14112-14120.
77. Zagato E, Pozzi C, Bertocchi A, et al: Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol 2020;5: 511-524.
78. Johansson ME, Hansson GC: Immunological aspects of intestinal mucus and mucins. Nat Rev Immunol 2016;16: 639-649.
79. Karve SS, Pradhan S, Ward DV, et al: Intestinal organoids model human responses to infection by commensal and Shiga toxin producing Escherichia coli. PLoS One 2017;12.
80. Betge J, Schneider NI, Harbaum L, et al: MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. Virchows Arch 2016;469: 255-265.
81. Dharmani P, Strauss J, Ambrose C, et al: Fusobacterium nucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. Infect Immun 2011;79: 2597-2607.
82. De Filippis F, Pellegrini N, Vannini L, et al: High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut 2016;65: 1812-1821.
83. Reuter C, Oelschlaeger TA: Enhancement of Mucus Production in Eukaryotic Cell and Quantification of Adherent Mucus by ELISA. Bio Protoc 2018;8.
84. MetaboAnalyst4.0 (https://www.metaboanalyst.ca/MetaboAnalyst/home.xhtml)
85. KEGG PATHWAY Database (https://www.kegg.jp/kegg/pathway.html)
86. Staudacher E: Mucin-type O-glycosilation in invertebrates. Molecules 2015;20: 10622-10640.
87. Kanagawa M, Toda T: Ribitol-phosphate-a newly identified posttranslational glycosylation unit in mammals: structure, modification enzymes and relationship to human diseases. J Biochem 2018;163: 359-369.
88. Yoshida-Moriguchi T, Campbell KP: Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology 2015;25: 702-713.
89. Wang ZE, Wu D, Zheng LW, et al: Effects of glutamine on intestinal mucus barrier after burn injury. Am J Transl Res 2018;10: 3833-3846.
90. Boren J, Lee WN, Bassilian S, et al: The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J Biol Chem 2003;278: 28395-28402.
91. Oshima T, Miwa H: Gastrointestinal mucosal barrier function and diseases. J Gastroenterol 2016;51: 768-778.
92. Akobeng AK, Elawad M, Gordon M: Glutamine for induction of remission in Crohn's disease. Cochrane Datebase Syst Rev 2016;2.
93. Kinosita M, Suzuki Y, Saito Y: Butyrate reduces colonic paracellular permeability by enhancing PPARγ activation. Biochem Biophys Res Commun 2002;293: 827-831.
94. Schwab M, Reynders V, Ulrich S, et al: PPARγ is a key target of butyrate- induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis 2006;11: 1801-1811.
95. Ulrich S, Wächtershäuser A, Loitsch SM, et al: Activation of PPARγ is not involved in butyrate-induced epithelial cell differentiation. Exp Cell Res 2005;310: 196-204.
96. Wächtershäuser A, Loitsch SM, Stein J: PPARγ is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun 2000; 272: 380-385.
97. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, et al: Dietary fructooligosaccharides increase intestinal permeability in rats. J Nutr 2005;135: 837-842.
98. Bullman S, Pedamallu CS, Sicinska E, et al: Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2007;358: 1443-1448.
99. Rotstein OD, Wells CL, Pruett TL, et al: Succinic acid production by Bacteroides fragilis. A potential bacterial virulence factor. Arch Surg 1987;122: 93-98.
論文の公開元へ
